Many breast and uterine cancers depend upon E2 for neoplastic initiation, development, or metastasis, and antiestrogen therapies remain the mainstay of treatment and prevention for ERα-expressing breast cancers. This evidence concerns the gene ESR1 and breast carcinoma.